2024
The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsMortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchRandomized controlled trialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-regressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-cause mortalityTemporal trendsStudy inclusion periodModern randomized controlled trialsBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, zwae298. PMID: 39298680, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-cause mortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB usersAssociation of cardiovascular diseases with cognitive performance in older adults
Park D, Jamil Y, Babapour G, Kim J, Campbell G, Akman Z, Kochar A, Sen S, Samsky M, Sikand N, Frampton J, Damluji A, Nanna M. Association of cardiovascular diseases with cognitive performance in older adults. American Heart Journal 2024, 273: 10-20. PMID: 38575050, PMCID: PMC11162917, DOI: 10.1016/j.ahj.2024.03.016.Peer-Reviewed Original ResearchAnimal Fluency TestOlder adultsCERAD-DRDSST scoresCardiovascular diseaseNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyCongestive heart failureFree of cardiovascular diseaseFluency testCardiovascular disease subtypesNutrition Examination SurveyAssociation of cardiovascular diseaseAnimal Fluency test scoreCognitive performanceLower cognitive performanceCoronary heart diseaseHeart failureCVD subtypesExamination SurveyAssess cognitive performanceAdultsCognitive functionHeart diseaseScores
2023
Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial
Jamil Y, Park D, Verde L, Sherwood M, Tehrani B, Batchelor W, Frampton J, Damluji A, Nanna M. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial. The American Journal Of Cardiology 2023, 214: 66-76. PMID: 38160927, PMCID: PMC10923116, DOI: 10.1016/j.amjcard.2023.12.045.Peer-Reviewed Original ResearchStable ischemic heart diseaseAnti-anginal agentIntensive medical therapyIschemic heart diseaseMedical therapyQOL metricsHeart diseaseFindings merit further researchMajor adverse cardiovascular eventsAnti-anginal treatmentBARI 2D trialGreater QoL improvementAdverse cardiovascular eventsMyocardial jeopardy indexCardiovascular eventsCause mortalityCardiovascular endpointsClinical confoundersPatient characteristicsDiabetes mellitusHeart failureTherapy intensityClinical outcomesQOL improvementMyocardial infarctionCarcinoid Heart Disease-Induced Right-Sided Heart Failure as a Culprit for Significant Ascites
Huang Y, Park D, Almoghrabi A, Nanna M. Carcinoid Heart Disease-Induced Right-Sided Heart Failure as a Culprit for Significant Ascites. Case Reports In Gastroenterology 2023, 17: 179-184. PMID: 36974060, PMCID: PMC10039415, DOI: 10.1159/000529633.Peer-Reviewed Original ResearchCarcinoid heart diseaseDiagnosis of carcinoid heart diseaseManagement of carcinoid heart diseaseSerum-ascites albumin gradientHeart diseaseAlcohol use disorderSignificant ascitesNeuroendocrine neoplasmsPortal hypertensionCase reportAlbumin gradientHeart failurePhysical examinationEarly diagnosisUse disorderAscitesFluid analysisPatient outcomesPeritoneal fluid analysisDiagnosisMultidisciplinary approachPatientsEarly interventionDiseaseRelevant specialists
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trials
2021
Moving the Field Forward: Untangling the Impact of Frailty on Patients With Advanced Heart Failure and on Prognosticating Outcomes
Clark KAA, Nanna MG. Moving the Field Forward: Untangling the Impact of Frailty on Patients With Advanced Heart Failure and on Prognosticating Outcomes. Journal Of Cardiac Failure 2021, 28: 775-777. PMID: 34936895, PMCID: PMC9106896, DOI: 10.1016/j.cardfail.2021.12.006.Peer-Reviewed Original Research180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study
Dodson JA, Hajduk AM, Murphy TE, Geda M, Krumholz HM, Tsang S, Nanna MG, Tinetti ME, Ouellet G, Sybrant D, Gill TM, Chaudhry SI. 180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study. Open Heart 2021, 8: e001442. PMID: 33452007, PMCID: PMC7813425, DOI: 10.1136/openhrt-2020-001442.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionReadmission risk modelSelf-reported health statusMyocardial infarctionFunctional mobilityOlder adultsHealth statusDays of AMIFirst diastolic blood pressureChronic obstructive pulmonary diseaseIschemic ECG changesProspective cohort studyDiastolic blood pressureObstructive pulmonary diseaseLength of stayInitial heart rateFinal risk modelSILVER-AMI StudyRisk modelInitial hemoglobinCohort studyReadmission ratesBlood pressureEjection fractionHeart failure
2020
Weight change in heart failure inpatients not associated with 30-day readmission
Nanna MG, Sullivan AE, Bazylevska V, Wong R, Murphy TE, Bellumkonda L, McNamara RL. Weight change in heart failure inpatients not associated with 30-day readmission. Future Cardiology 2020, 16: 289-296. PMID: 32286858, PMCID: PMC7607390, DOI: 10.2217/fca-2019-0047.Peer-Reviewed Original ResearchConceptsHF-specific readmissionsHeart failureWeight changeWeight lossHeart failure inpatientsHospital weight lossDecompensated heart failureShort-term readmissionHF inpatientsCause readmissionDischarge weightSingle centerReadmissionLogistic regressionPatientsInpatientsCauseAssociationWeight dataAdmission
2018
Long-Term Cognitive Decline After Newly Diagnosed Heart Failure
Hammond CA, Blades NJ, Chaudhry SI, Dodson JA, Longstreth WT, Heckbert SR, Psaty BM, Arnold AM, Dublin S, Sitlani CM, Gardin JM, Thielke SM, Nanna MG, Gottesman RF, Newman AB, Thacker EL. Long-Term Cognitive Decline After Newly Diagnosed Heart Failure. Circulation Heart Failure 2018, 11: e004476. PMID: 29523517, PMCID: PMC6072263, DOI: 10.1161/circheartfailure.117.004476.Peer-Reviewed Original ResearchConceptsIncident heart failureHeart failureYears of ageEjection fractionHF diagnosisAtrial fibrillationModified Mini-Mental State Examination scoresCommunity-based prospective cohort studyCognitive declineHistory of HFMini-Mental State Examination scoreLong-term cognitive declineModified Mini-Mental State ExaminationAtrial fibrillation statusComorbid atrial fibrillationMini-Mental State ExaminationProspective cohort studyGlobal cognitive abilityState Examination scoreHospital discharge summariesPublic health implicationsCohort studyClinical strokeCardiovascular healthAdjusted model